The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
The company is developing a blood-based liquid biopsy test based on the method to monitor 5-hydroxymethylcytosine levels in cell-free tumor DNA.
Ariel's laboratory-developed test analyzes 13 genes linked to pancreatitis, and the results are integrated into its new clinical decision support tool.
The firm has been piecing together a collection of acquisitions over recent years that expand its presence in the genomics market, particularly custom oligos.
The company also published a study describing ImmRay PanCan-D biomarker signature that it said could be used to detect early-stage pancreatic cancer.
The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
Of the six kits, the team found that Qiagen and Norgen's spin column tools recovered the highest amount of DNA across a range of base pair lengths.
The firm's automated AIR sample prep technology quickly images, sorts, and isolates single cells for downstream molecular analysis.
The tool uses magnetic, gold-coated electrodes to detect microRNA in blood within a concentration range of 10 attomolar to 1 nanomolar in 30 minutes.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.